Further, a prospective multicenter trial was conducted with the involvement of 11 patients diagnosed with EGFR mutation-positive NSCLC with leptomeningeal carcinomatosis and with the aim of evaluating the CSF penetration rates and the clinical efficacy of afatinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.